Morphine and other opioid drugs produce analgesia in humans and antinociception in animals by direct interaction with opioid receptor proteins located on neurons in the brain and spinal cord. Knowledge of the detailed relationship between the molecular structure of the opioid drug and the molecular conformation of the opioid receptor is essential to understand pharmacological action of opioids. Whereas mammalian CNS expresses three distinct opioid receptor genes (MOR1, DOR1, KOR1), each capable of mediating antinociception in mammals, amphibians appear to mediate the antinociception effects of mu, delta, and kappa-selective opioid agonists via a single opioid receptor, termed the 'unireceptor'. The Northern grass frog, Rana pipiens, will be used for all studies and the acetic acid test used for measuring opioid antinociception. For the first time, a systematic study of opioid receptor selectivity for producing antinociception will be made by in vitro and in vivo pharmacological techniques using novel methods in an amphibian model.
The specific aims are: 1) Determine the pharmacological selectivity of spinal opioid antinociception using highly-selective opioid antagonists and selective opioid agonists, and 2) Characterize the opioid binding sites in amphibian CNS tissue homogenates using radiolabeled highly-selective opioid antagonists and selective opioid agonists. Preliminary data are presented for each of these specific aims. The proposed results will elaborate our understanding of the molecular mechanisms of opioid drugs at opioid receptors with regard to opioid antinociception in animals and analgesia in humans. Additionally as our lab is the sole purveyor of opioid pharmacology using an earlier-evolved vertebrate model, the proposed studies are a unique examination of the functional evolution of opioid receptors. These studies challenge existing paradigms and further develop a new methodology for the study of opioids. Data obtained will be significant contributions to current understanding of the functional evolution of opioid receptors with regard to opioid ligand selectivity and mediation of antinociception. This knowledge will likely contribute to the understanding of the mechanisms of opioid receptor activation and may help guide the rational development of improved therapies where opioid drugs are used or abused.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15DA012448-01
Application #
2834838
Study Section
Special Emphasis Panel (ZRG1-IFCN-4 (01))
Program Officer
Thomas, David D
Project Start
1999-06-01
Project End
2001-05-31
Budget Start
1999-06-01
Budget End
2001-05-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Osu Center of Health Sciences
Department
Pharmacology
Type
Schools of Osteopathy
DUNS #
City
Tulsa
State
OK
Country
United States
Zip Code
74107
Stevens, Craig W (2015) Bioinformatics and evolution of vertebrate nociceptin and opioid receptors. Vitam Horm 97:57-94
Stevens, Craig W (2011) Analgesia in amphibians: preclinical studies and clinical applications. Vet Clin North Am Exot Anim Pract 14:33-44
Mohan, Shekher; Davis, Randall L; DeSilva, Udaya et al. (2010) Dual regulation of mu opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1ýý: evidence for opioid-immune crosstalk. J Neuroimmunol 227:26-34
Stevens, Craig W (2009) The evolution of vertebrate opioid receptors. Front Biosci (Landmark Ed) 14:1247-69
Stevens, Craig W; Martin, Kristin K; Stahlheber, Brad W (2009) Nociceptin produces antinociception after spinal administration in amphibians. Pharmacol Biochem Behav 91:436-40
Davis, Randall L; Buck, Daniel J; Saffarian, Neda et al. (2008) Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol 3:150-3
Brasel, Chris M; Sawyer, Gregory W; Stevens, Craig W (2008) A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function. Eur J Pharmacol 599:36-43
Davis, Randall L; Buck, Daniel J; Saffarian, Neda et al. (2007) The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J Neuroimmunol 186:141-9
Stevens, Craig W; Toth, Geza; Borsodi, Anna et al. (2007) Xendorphin B1, a novel opioid-like peptide determined from a Xenopus laevis brain cDNA library, produces opioid antinociception after spinal administration in amphibians. Brain Res Bull 71:628-32
Newman, Leslie C; Sands, Steven S; Wallace, David R et al. (2002) Characterization of mu, kappa, and delta opioid binding in amphibian whole brain tissue homogenates. J Pharmacol Exp Ther 301:364-70

Showing the most recent 10 out of 12 publications